EMA recommends authorization of Teizeild to delay Type 1 diabetes onset
This is the first drug to receive a recommendation for this preventative indication in the European Union
This is the first drug to receive a recommendation for this preventative indication in the European Union
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
ALBIS will present a selection of advanced materials from its broad healthcare portfolio
This collaboration turns kitting into a strategic advantage for sponsors and sites
Diversifying its portfolio to include late-phase antiviral agent
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Subscribe To Our Newsletter & Stay Updated